Pay in 4 interest-free payments of $6.55 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Novo Nordisk is the market leader: Ozempic (weekly injection for type 2 diabetes) Wegovy (higher-dose weekly injection for obesity) Rybelsus ( Oral tablets for diabetes Oral tablets for weight management is in phase 3 trials) Eli Lilly is the other major player: Mounjaro (weekly injection for type 2 diabetes) Zepbound (higherdose weekly injection for obesity) This duopoly meant that both stocks had an incredible run-up from 2020 to 2024
Duration: In many cases, fatigue associated with Mounjaro resolves as the body adapts to the medication
These include kidney damage, blindness, nerve problems, limb amputations, and even sexual dysfunction
Pini Orbach, Arkin Bio managing partner Arkin Capital raises $100M to back a dozen early-stage biotechs Arkin Capital has landed $100 million for its third early-stage biotech investment fund, which will support 10 to 12 drug development startups
(4) Mao Y, Tokudome T, Kishimoto I
